These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 36631717)

  • 21. Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study.
    Zheng Z; Liao W; Liu L; Cai S; Zhu H; Yin S
    Biomed Pharmacother; 2020 Feb; 122():109698. PubMed ID: 31918272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New Perspectives on Development of Curative Strategies for Chronic Hepatitis B.
    Feld JJ; Lok AS; Zoulim F
    Clin Gastroenterol Hepatol; 2023 Jul; 21(8):2040-2050. PubMed ID: 37080262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure.
    Moini M; Fung S
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss.
    Brakenhoff SM; de Man RA; Boonstra A; van Campenhout MJH; de Knegt RJ; van Bömmel F; van der Eijk AA; Berg T; Hansen BE; Janssen HLA; Sonneveld MJ
    Aliment Pharmacol Ther; 2021 Jan; 53(2):314-320. PubMed ID: 33222190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss.
    Xue Y; Zhang M; Li T; Liu F; Zhang LX; Fan XP; Yang BH; Wang L
    World J Gastroenterol; 2021 Apr; 27(14):1497-1506. PubMed ID: 33911470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B.
    Jeng WJ; Chen YC; Chien RN; Sheen IS; Liaw YF
    Hepatology; 2018 Aug; 68(2):425-434. PubMed ID: 29108132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
    J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.
    Song JC; Min BY; Kim JW; Kim JY; Kim YM; Shin CM; Lee SH; Hwang JH; Jeong SH; Kim N; Lee DH
    Korean J Hepatol; 2011 Dec; 17(4):268-73. PubMed ID: 22310791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B].
    Lu FM; Wang J; Chen XM; Jiang JN; Zhang WH; Zhao JM; Ren H; Hou JL; Xia NS
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):105-110. PubMed ID: 28297795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RNA interference as a novel treatment strategy for chronic hepatitis B infection.
    Hui RW; Mak LY; Seto WK; Yuen MF
    Clin Mol Hepatol; 2022 Jul; 28(3):408-424. PubMed ID: 35172540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.
    Zoulim F; Carosi G; Greenbloom S; Mazur W; Nguyen T; Jeffers L; Brunetto M; Yu S; Llamoso C
    J Hepatol; 2015 Jan; 62(1):56-63. PubMed ID: 25176615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
    Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
    J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B.
    Striki A; Manolakopoulos S; Deutsch M; Kourikou A; Kontos G; Kranidioti H; Hadziyannis E; Papatheodoridis G
    Liver Int; 2017 Nov; 37(11):1642-1650. PubMed ID: 28345181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients.
    Chu JH; Huang Y; Xie DY; Deng H; Wei J; Guan YJ; Li GJ; Zeng YL; Yang JH; Chen XY; Shang J; Li JB; Gao N; Gao ZL
    J Viral Hepat; 2022 Sep; 29(9):765-776. PubMed ID: 35718996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy.
    Hsu WF; Chen CF; Lai HC; Su WP; Lin CH; Chuang PH; Chen SH; Chen CH; Wang HW; Huang GT; Peng CY
    Liver Int; 2018 Apr; 38(4):627-635. PubMed ID: 28857411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
    Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT.
    Lim SG; Yang WL; Ngu JH; Chang J; Tan J; Ahmed T; Dan YY; Lim K; Lee YM; Lee GH; Tan PS; Wai KL; Phyo WW; Khine HHTW; Lee C; Tay A; Chan E
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):e228-e250. PubMed ID: 33895361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients.
    Wang WX; Jia R; Gao YY; Liu JY; Luan JQ; Qiao F; Liu LM; Zhang XN; Wang FS; Fu J
    Front Immunol; 2022; 13():894410. PubMed ID: 35958609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A 2020 update on the progress of treatment and new drug clinical trials for hepatitis B].
    Jia JD; Niu JQ; You H; Kong YY; Hou JL
    Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):97-101. PubMed ID: 33685074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients.
    Li M; Sun F; Bi X; Lin Y; Yang L; Lu Y; Zhang L; Wan G; Yi W; Zhao L; Xie Y
    Virol Sin; 2022 Jun; 37(3):390-397. PubMed ID: 35257963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.